move up move left move right move bottom

XARELTO® Starter Pack

The only pack available for initiation of DVT and/or PE treatment

The treatment you know in a convenient package

  • Provides therapy for the first 30 days when patients are most vulnerable to a recurrent event1
  • Helps provide a seamless transition from diagnosis to follow-up
  • A single-agent treatment approach from the time of diagnosis OR following initial treatment with a parenteral anticoagulant

Prescribing the XARELTO® Starter Pack

  • To prescribe, simply write “XARELTO® Starter Pack for DVT and/or PE treatment. Take as directed.”
  • First 30 days of XARELTO® treatment included, with easy-to-follow dosing instructions2:
    • 15 mg twice daily with food (42 tablets total) for the first 21 days
    • 20 mg once daily with food (9 tablets total) for Days 22-30
  • No cost to elgible patients when used with the Janssen CarePath Trial Offer for XARELTO®. Terms and conditions apply
  • Available through retail and outpatient pharmacies






Indication and Important saftey Information


  • Reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (AF). There are limited data on the relative effectiveness of XARELTO® (rivaroxaban) and warfarin in reducing the risk of stroke and systemic embolism when warfarin therapy is well controlled.
  • Treatment of deep vein thrombosis (DVT).
  • Treatment of pulmonary embolism (PE).
  • Reduction in the risk of recurrence of DVT and of PE following initial 6 months treatment for DVT and/or PE.
  • Prophylaxis of DVT, which may lead to PE in patients undergoing knee replacement surgery.
  • Prophylaxis of DVT, which may lead to PE in patients undergoing hip replacement surgery.


  1. Limone BL, Hernandez AV, Michalak D, Bookhart BK, Coleman CI. Timing of recurrent venous thromboembolism early after the index event: a meta-analysis of randomized controlled trials. Thromb Res. 2013;132(4):420-426.
  2. Data on file. Janssen Pharmaceuticals, Inc. Data as of 8/8/14.